summari report somewhat mix result
introduc guidanc direct in-lin
expect compani report ep penni
ahead consensus/our forecast sale slightli
consensus/our estim ep beat primarili reflect
lower-than-expect tax rate manag guid
includ estim net benefit extra
sell week less ration sku consum exclud
adjust underli sale growth closer
midpoint rang repres slight acceler
expect report ep guidanc
street estim differ part due
share count although entir surpris us street
like disappoint
below-expect ep guidanc
howev given jnj earn track record solid growth
momentum see guidanc like somewhat conserv
start year sale estim unchang
lower ep estim price
target repres ep estim
sale miss expect ep penni ahead
expect report sale fall shi
consensu estim rel consensu
medic devic consum sale bit softer expect
adjust oper sale growth slow
due deceler pharma medic devic specif
sale growth deceler medic devic vs
due tougher yr/yr comp japan stock benefit
growth also slow pharma vs
essenti stabl consum vs
despit slightli sale miss ep beat consensus/our
forecast penni ep differ vs model primarili
reflect lower tax rate vs estim partli
off-set lower sale gross margin vs estim
net incom vs mm estim
continu next page
compani data secur llc estim reuter
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
continu previou page
guid adjust oper sale growth guidanc includ
estim net benefit addit ship day less ration consum sku
exclud benefit estim top-lin growth would closer midpoint rang
would in-lin expect growth repres slight acceler
extra ship day benefit headwind sku
ration expect affect mostli year guidanc exclud fx headwind
expect mostli affect believ guidanc realist achiev
potenti upsid stronger perform pharmaceut view forecast sale
adjust oper sale growth latter includ benefit extra week
sale growth expect acceler medic devic md pharma expect md
sale growth continu acceler within rang market growth
manag estim sell day repres growth headwind
md larg revers sale growth also expect acceler
slightli driven part growth key franchis new product
neutral loe loss exclus headwind growth outlook includ tailwind
extra week impact expect similar across segment us/ou forecast
adjust oper sale growth pharma medic devic includ
benefit extra ship day
consum busi select de-emphasize ration global consum
sku specif babi beauti increas focu improv profit move
expect reduc consum sale growth littl program mostli impact ou
market impact growth manag emphas focu busi like beauti
over-the-counter continu make invest includ potenti acquisit could see addit
portfolio optim like rest consum believ jnj net incom io
guidanc like includ level asset sale gain divestitur forecast
consum adjust oper sale growth includ benefit extra week
drag sku ration
ep guidanc essenti in-lin expect guid report ep
growth midpoint rang ex-fx growth outlook consist
preview manag like guid conserv start year
guidanc rang fall consensu forecast manag note miscalcul share
count probabl ad penni street ep ep guidanc assum yr/yr
margin expans mostli driven sg cog leverag compani continu invest
net io guidanc nearli yr/yr still higher
expect given prior manag commentari net io would decreas yr/yr given
jnj earn track record solid growth momentum top-lin see potenti upsid
ep guidanc year progress forecast report ep growth
med-tech investor day highlight robotic/surg platform host bi-annu med-tech
investor meet may nyc compani plan showcas extens pipelin across
segment expect updat develop robotics/digit platform key focu
meet notabl investor meet focu medic devic busi plan
discuss consum busi forum
price target nc
price target impli cash ep base sum-of-the-part
analysi risk includ uncertainti on-going opioid/talc litig pipelin delay unexpect
deterior industri
expect growth acceler eas multipl headwind new product
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product intervent orthoped surgic vision compani report sale
underli growth year-over-year
